|
L-carnitine supplementation ameliorates insulin resistance in critically ill acute stroke patients: a randomized, double-blinded, placebo-controlled clinical trial
|
Malihe Nejati   , Saeed Abbasi , Shadi Farsaei , Fatemeh Shafiee |
|
|
|
Abstract: (279 Views) |
Introduction: Insulin resistance (IR) can negatively affect clinical outcomes in acute ischemic stroke (IS) patients. Safe and cost-saving interventions are still needed to improve glycemic indices in this population. The primary objective was to evaluate L-carnitine (LC) effects in acute IS patients" homeostatic model assessment of IR (HOMA-IR).
Methods and Materials: In this randomized, double-blind placebo-controlled clinical trial, critically ill IS patients were allocated to receive daily oral L-carnitine (1.5 g) or a placebo for six days. Fasting serum levels of glucose, insulin, C-reactive protein, LC, and HOMA-IR were measured on days 1 and 7. Mechanical ventilation duration, ICU/hospital duration, illness severity score, sepsis, and death events were assessed.
Results: Forty-eight patients were allocated to the research groups, 24 patients in each group, and all were included in the final analysis. LC administration showed a decrease in the mean difference of HOMA-IR and insulin levels at day 7 compared to placebo, -0.94 ± 1.92 vs 0.87± 2.24 (P = 0.01) and -2.26 ± 6.81 vs 0.88 ± 4.95 (P = 0.03), respectively. However, LC administration did not result in significant improvement in clinical outcomes compared to placebo.
Conclusion: Supplementation of L-carnitine improved the HOMA-IR index in acute IS patients admitted to the critical care unit. Supplementation of LC would be a potential option to help control IR in critically ill acute IS patients.
|
|
| Keywords: Critical care, Ischemic stroke, L-carnitine, HOMA-IR, Hyperglycemia |
|
|
Full-Text [PDF 259 kb]
(44 Downloads)
|
Type of Study: Research |
Subject:
General
Received: 2023/12/15 | Accepted: 2023/08/23 | Published: 2023/08/23
|
|
|
|
|
|
|
| Send email to the article author |
|
|
|
| Add your comments about this article |
|
|
|
